You are here

FAECAL CARRIAGE OF ANTIBIOTIC RESISTANT ESCHERICHIA COLI AMONG HEALTHY INDIVIDUALS AND HOSPITAL PATIENTS.

Journal Name:

Publication Year:

Abstract (2. Language): 
Background: Microbial resistance to drugs has become a global publichealth problem compromising the efficacy of antimicrobial chemotherapy. The phenomenon of drug resistance is not restricted to pathogenic bacteria; it also involves the commensal microbiota of humans. There is worldwide concern about the spread of antibiotic resistant microbiota causes of community as well as hospital acquired infections. Methods: This prospective study comprising of 100 faecal samples were processed and the isolates were identified by using standard microbiological techniques and antibiotic sensitivity was determined by Kirby Bauer disc diffusion method. Result: Out of 100 samples 50 were from community and 50 from hospital patients. In this study it was noted that the antibiotic resistance was more in hospital patients than in healthy individuals of community. The resistance patterns of hospital patients and healthy individuals of community as follows ampicillin, 68% and 36%; amoxyclav, 66% and 18%; ciprofloxacin, 56% and 18%; co-trimoxazole, 54% and 22%; cefotaxime, 50% and 10%; gentamicin, 30% and 4%; piperacillin-tazobactum, 30% and 0%; cefaparazone-sulbactum, 24% and 0%; amikacin, 14% and 0%; imipenem, 12% and 2% of the tested isolates, respectively. Conclusion: It can be concluded that faecal carriage of antibiotic resistant E. coli can causes of hospital-acquired infections and occasionally causes community-acquired infections. So, it is recommended that it necessitates prevention of infections by conducting the infection control programmes and implementation of surveillance for this emerging antibiotic resistance phenomenon.
FULL TEXT (PDF): 
283-289

REFERENCES

References: 

1. World Health Organization. Global strategy for containment of antimicrobial resistance. Geneva: WHO, 2001.
2. Avorn JL, Barrett JF, Davey PG, McEwen SA, O'Brien TF, Levy SB. Antibiotic resistance: synthesis of recommendations
Available Online At www.ijprbs.com
Research Article
G Prashanth Kumar, IJPRBS, 2013; Volume 2(3): 283-289
by expert policy groups. Alliance for the Prudent Use of Antibiotics [WHO/CDS/CSR/DRS/2001.10]. Geneva: World Health Organization, 2001.
3. Falagas, M.E. and D.E. Karageorgopoulos, 2008. Pandrug resistance (PDR), extensive drug resistance (XDR) and multidrug resistance (MDR) among Gram negative bacilli: need for international harmonization in terminology. Clin Infect Dis., 46: 1121-2.
4. Bisson G, Fishman NO, Patel JB, Edelstein PH Klebsiella species: risk factors for colonization and impact of antimicrobia, and Lautenbach E. (2002) Extended-spectrum beta-lactamaseproducing Escherichia coli and l formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol
23:254-260.
5. Bonten, M., Stobberingh E, Philips J, and Houben A. 1992. Antibiotic resistance of Escherichia coli in fecal samples of healthy people in two different areas in an industrialized country. Infection 20:258¬262.
6. Clinical Laboratory Standards Institute (CLSI) guidelines. Performance standards for antimicrobial susceptibility testing:
ISSN: 2277-8713 IJPRBS
Twentieth informational supplement. CLSI Document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
7. Abdulla kader A, et al. Fecal Carriage of Extended- spectrum P-Lactamase-Producing Escherichia coli and Klebsiella pneumonia in Patients and Asymptomatic Healthy Individuals. Infect Control Hosp
Epidemiol 2007; 28:1114-1116.
8. Bartolonie A et al. Multidrug-resistant Commensal Escherichia coli in Children, Peru and Bolivia. Emerging Infectious
Diseases 2006; 12, 6: 907-913.

Thank you for copying data from http://www.arastirmax.com